Skip to main content
Premium Trial:

Request an Annual Quote

Left BARDA Behind

Rick Bright is no longer the head of the Biomedical Advanced Research and Development Authority, the agency at the center of the US response to the SARS-CoV-2 pandemic, Stat News reports.

BARDA has been supporting efforts by Johnson & Johnson and Moderna to develop vaccines against SARS-CoV-2, and, as Stat News notes, the agency saw its budget more than triple as part of the recent coronavirus stimulus package. CNN adds that Bright had led BARDA since 2016 and, before that, he directed its Influenza and Emerging Infectious Diseases Division.

But the reason for Bright's departure is unclear, Stat News adds, noting there have been reports of "chafing" between him and Bob Kadlec, the Department of Health and Human Services assistant secretary for preparedness and response. 

An HHS spokesperson tells Stat News that Bright is moving to the National Institutes of Health to work on diagnostics. "Bright will transfer the skills he has applied as Director of the Biomedical Advanced Research and Development Authority (BARDA) to the National Institutes of Health, as part of a bold plan to accelerate the development and deployment of novel point-of-care testing platforms," says HHS spokesperson Caitlin Oakley, according to Bloomberg News.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.